Sellas Life Sciences Group Inc. SLS
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy that targets the Wilms tumor 1 (WT1) protein and addresses hematologic maligna…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees15
TickerSLS
Statistics
Market Cap$1.38B
Revenue (TTM)—
Net Income-$26.9M
Net Margin—
EPS$-0.25
P/E-31.24
P/S—
P/B13.09
EV/EBITDA-47.24
ROE-43.6%
Dividend Yield—
Price$7.63
Data: Twelve Data · Revenue = mcap / P/S